Management of Crohn's disease from efficacy, quality of life and health economic perspectives

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 3, Issue 5, 2003, Pages 587-598

  Ghosh, Subrata ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Azathioprine; Inflammatory bowel disease; Infliximab; Pharmacoeconomics; Quality of life

Indexed keywords

ALICAFORSEN; ALPHA2A INTERFERON; AZATHIOPRINE; BUDESONIDE; C REACTIVE PROTEIN; CORTICOSTEROID; ETANERCEPT; GAMMA INTERFERON; HYDROCORTISONE; INFLIXIMAB; INTERLEUKIN 1BETA; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; NEUTROPHIL CYTOPLASMIC ANTIBODY; PENTOXIFYLLINE; PLACEBO; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 10; STEROID; TACROLIMUS; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY; UNINDEXED DRUG;

CLINICAL TRIAL; COLON CROHN DISEASE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; FIRST PASS EFFECT; GASTROINTESTINAL MUCOSA; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH ECONOMICS; HOSPITALIZATION; HUMAN; LIVER TOXICITY; OUTCOMES RESEARCH; PATHOGENESIS; PHARMACOECONOMICS; PHYSICIAN; PREVALENCE; QUALITY OF LIFE; REMISSION; REVIEW; SIDE EFFECT; STEROID THERAPY; SYMPTOMATOLOGY; VALIDATION PROCESS; WOUND HEALING;

EID: 0142248283     PISSN: 14737167     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737167.3.5.587     Document Type: Review

References (67)

1. Bonen DK, Cho JH. The genetics of inflammatory bowel disease. Gastroenterology 124(2), 521-536 (2003).
2. Ahmad T, Armuzzi A, Bunce M et al. The molecular classification of the clinical manifestations of Crohn's disease. Gastroenterology 122(4), 854-866 (2002).
3. Moum B, Ekbom A, Vatn MH et al. Clinical course during the first year after diagnosis in ulcerative colitis and Crohn's disease. Results of a large, prospective population-based study in southeastern Norway, 1990-1993. Scand. J. Gastroenterol. 32(10), 1005-1012 (1997).
4. Faubion WA, Loftus EV, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population based study. Gastroenterology 121(2), 255-260 (2001).
5. Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 35(3), 360-362 (1994).
6. Arnott IDR, Watts D, Ghosh S. Is clinical remission the optimum therapeutic goal in the treatment of Crohn's disease? Aliment Pharmacol. Ther. 16(5), 857-867 (2002).
7. Tibble JA, Sigthorson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 119(1), 15-22 (2000).
8. Casellas F, Lopez-Vivancos J, Casado A, Malagelada JR. Factors affecting health related quality of life of patients with inflammatory bowel disease. Qual. Life Res. 11(8), 775-781 (2002).
9. Konig HH, Ulshofer A, Gregor M et al. Validation of the EuroQOL questionnaire in patients with inflammatory bowel disease. Euro J. Gastroenterol. Hepatol. 14(11), 1205-1215 (2002).
10. Feagan BG. Economic issues in Crohn's disease - assessing the effects of new treatments on health-related quality of life. Aliment Pharm. Ther. 13(Suppl. 4), 29-37 (1999).
11. Blomqvist P, Ekbom A. Inflammatory bowel diseases: healthcare and costs in Sweden in 1994. Scand. J. Gastroenterol. 32(11), 1134-1139 (1997).
12. Hay AR, Hay JW. Inflammatory bowel disease: medical cost algorithms. J. Clin. Gastroenterol. 14(4), 318-327 (1992).
13. Hay JW. Hay AR. Inflammatory bowel disease: costs-of-illness. J. Clin. Gastroenterol. 14(4), 309-317 (1992).
14. Feagan BG, Vreeland MG, Larson LR et al. Annual cost of care for Crohn's disease: A payor perspective. Am. J. Gastroenterol. 95(8), 1955-1960 (2000).
15. Cohen RD, Larson LR, Roth JM et al. The cost of hospitalization in Crohn's disease. Am. J. Gastroenterol. 95(2), 524-530 (2000).
16. Bernstein CN, Papineau N, Zajaczkowski J et al. Direct hospital costs for patients with inflammatory bowel disease in a Canadian tertiary care university hospital. Am. J. Gastroenterol. 95(3), 677-683 (2000).
17. Trallori G, Messori A. Drug treatments for maintaining remission in Crohn's disease. A lifetime cost-utility analysis. Pharmaco Economics 11, 444-453 (1997).
18. Blomqvist P, Feltelius N, Lofberg R, Ekbom A. A 10-year survey of inflammatory bowel diseases-drug therapy, costs and adverse reactions. Aliment Pharmacol. Ther. 15(4), 475-481 (2001).
19. Irvine EJ, Greenberg GR, Feagan BG et al. Quality of life improves with budesonide therapy for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. Inflamm. Bowel Dis. 6(3), 181-187 (2000).
20. Van Dullemen HM, van Deventer SJH, Hommes DW et al. Treatment of Crohn's disease with antitumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109(1), 129-135 (1995).
21. Targan SR, Hanauer SB, van Deventer SJH et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor-α for Crohn's disease. N. Engl. J. Med. 337(15), 1029-1035 (1997).
22. Present DH, Rutgeerts P, Targan S et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N. Engl. J. Med. 340(18), 1398-1405 (1999).
23. Rutgeerts P, D'Haens G, Targan A et al. Efficacy and safety of retreatment with antitumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 117(4), 761-769(1999).
24. Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ. Successful management of Crohn's disease of the ileoanal pouch with infliximab. Gastroenterology 117(2), 429-432 (1999).
25. Arnort IDR, McDonald D, Williams A, Ghosh S. Clinical use of infliximab in Crohn's disease: the Edinburgh experience. Aliment Pharmacol. Ther. 15(10), 1639-1646 (2001).
26. Ricart E, Panaccione R, Loftus E et al. Infliximab for Crohn's disease in clinical practice at the mayo clinic. The first 100 patients. Am. J. Gastroenterol. 96(3), 722-729 (2001).
27. Kugathasan S, Werlin S, Martinez A, Rivera MT, Heeikenen JB, Binion DG. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. Am. J. Gastroenterol. 95(11), 3189-3194 (2000).
28. Serrano MS, Schmidt-Sommerfeld E, Kilbaugh TJ et al. Use of infliximab in pediatric patients with inflammatory bowel disease. Ann. Pharmacother. 35(7-8), 823-828 (2001).
29. Nikolaus S, Raedler A, Kuhbacker T, Sfikas N, Folsch UR, Schreiber S. Mechanisms in figure of infliximab for Crohn's disease. Lancet 356(9240), 1475-1479(2000).
30. National Institute of Clinical excellence (NICE). Guidance on the use of infliximab for Crohn's disease. Technology Appraisal Guidance 40, April (2002).
31. Clark W, Raftery J, Song F, Barton P, Cummins C, Fry-Smith A. Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn's disease. Health Technology Assess. 7(3), 1-78 (2003).
32. Feagan BG, Enns R, Fedorak RN et al. Infliximab for the treatment of Crohn's disease: efficacy, safety and pharmacoeconomics. Can. J. Clin. Pharmacol. 8(4), 188-198 (2001).
33. Rubinstein JH, Chong RY, Cohen RD. Infliximab decreases resource use among patients with Crohn's disease. J. Clin. Gastroenterol, 35(2), 151-156 (2002).
34. Mitton OR. Funding the new biologics - a health economic critique of the CCOHTA report - infliximab for the treatment of Crohn's disease. Can. J. Gastroenterol. 16(12), 873476 (2002).
35. Baert F, Norman M, Vermiere S et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N. Engl. J. Med. 348(7), 601-608 (2003).
36. Farrell RJ, Alsahli M, Jeen Y, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 124(4), 917-924 (2003).
37. Kinney T, Rawlins M, Kozarek R, France R, Patterson D. Immunomodulators and on demand therapy with infliximab in Crohn's disease: clinical experience with 400 infusions. Am J. Gastroenterol. 98(3), 608-612(2003).
38. Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet 359(9317), 1541-1549 (2002).
39. Stack WA, Mann SD, Roy AJ et al. Randomized controlled trial of CDP571 antibody to tumour necrosis factor-α in Crohn's disease. Lancet 349(9051), 521-524 (1997).
40. Sandborn WJ, Feagan BG, Hannuer SB et al. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology 120, 1330-1338(2001).
41. Fedorak RN, Gangl A, Elson CO et al. Recombinant human interleukin 10 in the treatment of patients with mild-to-moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Co-operative Study Group. Gastroenterology 119(6), 1473-1482 (2000).
42. Colombel JF, Rutgeerts P, Malchow H et al. Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease. Gut 49 (1), 42-46 (2001).
43. Schreiber S, Fedorak RN, Nielsen OH et al. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Gastroenterology 119(6), 1461-1472 (2000).
44. Canva-Delcambre V, Jacquot S, Robinet E et al. Treatment of severe Crohn's disease with antiCD4 monoclonal antibody. Aliment Pharmacol. Ther 10(5), 721-727 (1996).
45. Sands BE, Bank S, Sninsky CA et al. Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease. Gastroenterology 117(1), 58-64 (1999).
46. Schreiber S, Nikolaus S, Malchow H et al. Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease. Gastroenterology 120(6), 1339-1346 (2001).
47. Gordon FH, Lai CWY, Hamilton MI et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to α4 integrin in active Crohn's disease. Gastroenterology 121(2), 268-274 (2001).
48. Ghosh S, Goldin E, Gordon FH et al. Natalizumab for active Crohn's disease. N. Engl. J. Med. 348(1), 24-32 (2003).
49. Lowry PW, Weaver AL, Tremaine WJ, Sandborn WJ. Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment-refractory Crohn's disease perianal fistulae. Inflamm. Bowel Dis. 50), 239-245 (1999).
50. Ferguson A, Glen M, Ghosh S. Crohn's disease: nutrition and nutritional therapy. Balliere's Clin. Gastroenterol. 12(1), 93-114 (1998).
51. Griffiths AM, Ohlsson A, Sherman PM, Sutherland LR. Meta-analysis of enteral nutrition as a primary treatment of active Crohn's disease. Gastroenterology 108(4), 1056-1067 (1995).
52. Fernandez-Banares F, Cabre E, Esteve-Comas M, Gassul MA. How effective is enteral nutrition in inducing clinical remission in active Crohn's disease? A meta-analysis of the randomized clinical trials. J. Parenter. Enteral. Nutr. 19(5), 356-364 (1995).
53. Gui GP, Thomas PRS, Tizard MLV et al. Two-year-outcomes analysis of Crohn's disease treated with rifabutin and macrolide antibiotics. J. Antimicrob. Chemother 39(3), 393-400(1997).
54. Thomas GAO, Swift GL, Green JT et al. Controlled trial of antituberculous chemotherapy in Crohn's disease: a five year follow-up study. Gut 42(4), 497-500 (1998).
55. Borgaonkar K MacIntosh D, Fardy J, Simms L. Antituberculous therapy for maintaining remission of Crohn's disease. Cochrane Database Syst. Rev. 2:CD000299 (2000).
56. Weinstein TA, Sciubba JJ, Levine J. Thalidomide for the treatment of oral aphthous ulcers in Crohn's disease. J. Pediatr: Gastroenterol. Nutr. 28 (2), 214-216 (1999).
57. Ehrenpreis ED, Kane SV, Cohen LB et al. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology 117(6), 1271-1277 (1999).
58. Vasiliauskas EA, Kam LY, Abreu-Martin MT et al. An open-label pilot study of low-dose thalidomide in chronically active, steroid dependent Crohn's disease. Gastroenterology 117(6), 1278-1287 (1999).
59. Hommes D, van den Blink B, Plasse T et al. Inhibition of stress-activated MAPKs induces clinical improvement in moderate-to-severe Crohn's disease. Gastroenterology 122(1), 7-14 (2002).
60. Neurath MF, Wanitschke F, Peters M et al. Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease. Gut 44(5), 625-628 (1999).
61. Miehsler W, Reinisch W, Moser G et al. Is mycophenolate mofetil an effective alternative in azathioprine-intolerant patients with chronic active Crohn's disease? Am J. Gastroenterol. 96(3), 782-787(2001).
62. Casson DH, Eltumi M, Tomlin S et al. Topical tacrolimus may be effective in the treatment of oral and perineal Crohn's disease. Gut 47(3), 436-440 (2000).
63. Sandborn WJ. Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn's disease. Am. J. Gastroenterol. 92(5), 876-879 (1997).
64. Ierardi E, Principi M, Francavilla R et al. Oral tacrolimus long-term therapy in patients with Crohn's disease and steroid resistance. Aliment Pharmacol. Ther. 15(3), 371-377 (2001).
65. Belluzzi A, Brignola C, Campieri M et al. Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. N. Engl. J. Med. 334(24), 1557-1560 (1996).
66. Lorenz-Meyer H, Bauer P, Nicolay C et al. Omega-3 fatty acids and low carbohydrate diet for maintenance of remission in Crohn's disease. A randomized controlled multicenter trial. Scand. J. Gastroenterol. 31(8), 778-785 (1996).
67. Bodger K. Cost of illness of Crohn's disease. PharmacoEconomics 20(10), 639-652 (2002).